Do people with multiple sclerosis have an increased risk of cancer? Dr. Kamal Kant Kohli11 Oct 2024 9:30 PM ISTA new study has found some cancers to be slightly more frequent in people with multiple sclerosis (MS) than in people without MS. The study is...
Why Hospitals Need to Focus More on Personalize and Customize Precision Treatment in Oncology? - Dr Manoj Lokhande Dr Manoj Lokhande16 July 2024 3:23 PM IST Offering tailor-made treatment for patients will bring a revolutionary change and successful prognosis of cancer. This article highlights the...
Harmonizing Adult Vaccination Guidelines in India: Need of the Hour (Prof) Dr Agam Vora6 Jun 2024 12:36 PM ISTA. Need for Adult ImmunizationVaccine-preventable diseases (VPDs) are among the various diseases that threaten India's healthcare system. From this...
Ten Recent Landmark Trials Across Oncology - Dr Vidit Kapoor Dr Vidit Kapoor10 Feb 2024 1:06 PM IST The field of Oncology has witnessed a transformative journey over the last decade, marked by groundbreaking discoveries and advancements that ...
Safety of Ranitidine: A Fresh Look at an Old Gem Dr. Kamal Kant Kohli23 Nov 2023 11:09 AM ISTThe introduction of histamine type 2 receptor antagonists (H2RAs) has revolutionised the management of acid-related disorders. Ranitidine has been...
Long-term PPI Use and Increased Cancer Risk: An Unrevealed Truth Dr. Kamal Kant Kohli2 Nov 2023 11:15 AM ISTReviewing Proton Pump Inhibitors:Proton pump inhibitors (PPIs) are commonly prescribed to reduce stomach acid levels in managing gastroesophageal...
Countering Post-operative Wound Inflammation with Trypsin-Bromelain-Rutoside Combination Dr. Kamal Kant Kohli14 April 2023 11:30 AM ISTIt has been well established that Systemic enzyme therapy (SET) aids better and faster healing when compared to usual anti-inflammatory drugs like...
Casirivimab and imdevimab in patients admitted to hospital with COVID-19: RECOVERY Trial Dr. Kamal Kant Kohli9 March 2022 5:19 PM ISTCasirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor-binding domain of the SARS-CoV-2...
Quick Review: Effectiveness of REGEN-COV antibody cocktail against B.1.617.2 (delta) variant of SARS-CoV-2 Dr. Kamal Kant Kohli1 Feb 2022 12:34 PM ISTCasirivimab plus imdevimab antibody cocktail (REGEN-COV) has been shown to reduce viral load and prevent symptomatic disease in household contacts of...
HuCare Quality Improvement Strategy: Improving health-related QOL during cancer treatment Dr Nirali Kapoor25 Nov 2021 9:00 AM ISTIndividuals with cancer experience a wide range of psychosocial health needs, encompassing mental, emotional, social, and spiritual aspects of...
Casirivimab-Imdevimab Treatment in Mild to Moderate COVID-19: A Real-World Evidence Dr. Kamal Kant Kohli19 Oct 2021 12:00 PM ISTCasirivimab and Imdevimab are two non-competing, high-affinity human IgG1 anti-SARS- CoV-2 monoclonal antibodies that bind non-competitively to the...
Use of computer-assisted colonoscopies reduce rate of missed lesions, finds study Hina Zahid24 Sept 2021 9:30 AM ISTBOSTON - Colorectal cancer is the third most diagnosed cancer and the second leading cause of cancer deaths in the United States. Regular screening...
